ASX Healthcare Stocks Reveal a Widening Valuation Gap

CSL has fallen by roughly half from its 52-week high. Cochlear is down well over half. Pro Medicus has dropped roughly a third from its peak. CSL, Cochlear and Pro Medicus rank among the largest, most established names on the ASX healthcare boards. The scale of their repricing says more about positioning than about business performance.

Healthcare's Largest Names Have Repriced Together, at Different Speeds

CSL, Cochlear, ResMed and Pro Medicus have all moved down over the past 12 months, though not by equal amounts. Cochlear has fallen the furthest, down well over half. CSL follows at roughly half, Pro Medicus at roughly a third, and ResMed at just under a quarter, the smallest decline of the four but still a meaningful de-rating. A single company missing on execution does not produce a synchronised decline across four businesses with different products, different customers and different growth profiles, even where the magnitude varies.

"Valuations across ASX healthcare leaders have reduced significantly off elevated prior levels. This has been a sector-wide phenomenon, not a reflection of business quality." - Emanuel Datt, Chief Investment Officer, Datt Capital, says

Sector Degrossing Explains the Scale of the Move

Healthcare carried some of the highest valuation multiples on the ASX through the growth-at-any-price cycle. Institutional positioning unwinds indiscriminately at that scale. Funds reduce exposure across the names they hold most, concentrating the selling in the largest, most liquid healthcare stocks first. Multiple compression follows, independent of any change in earnings, market share or clinical demand.

Smaller Healthcare Names Have Absorbed a Second Round of Selling

Sector degrossing extends beyond the large caps. As funds trim healthcare weightings, the reduction flows down to smaller, less liquid names in the same sector, which sell off further on lighter volume and less analyst coverage. The result is a widening dispersion between share price and underlying business performance the further down the market cap curve an investor looks.

"Smaller companies have sold off due to this sector degrossing, often more sharply than the fundamentals justify." - Emanuel notes

The Opportunity Sits in the Gap Between Price and Quality

A valuation reset driven by positioning is a different signal to investors than a genuine fundamental downgrade tied to weaker earnings power or competitive position. CSL's plasma therapies franchise, Cochlear's implant market share, ResMed's sleep and breathing platform and Pro Medicus's enterprise imaging contracts have held up at a rate their share prices do not reflect. Balance sheet strength is one of the clearer ways to test that gap, since a business funding growth from a position of financial strength is better placed to absorb a valuation reset than one relying on market sentiment to stay afloat. Datt Capital has applied this same distinction before, highlighting that disciplined research shaped its response to a sentiment-driven sell-off in a healthcare holding that later recovered once the market re-assessed the business against the price.

Unloved Sectors Are Where Active Managers Earn Their Fee

Passive strategies track the index down when a sector is degrossed, regardless of whether the underlying businesses still meet the bar for inclusion. An active fund manager with a research-led process is positioned to distinguish a sector-wide valuation reset from a genuine change in business quality, then act on that distinction while capital continues flowing out of the sector. Datt Capital's Absolute Return Fund was ranked in the top 10 equity long-only funds for 2025, a result built on this kind of sector-agnostic, research-led positioning.

"Good opportunities may be found in unloved sectors. That is precisely where disciplined, research-led analysis earns its keep." - Emanuel says

Portfolio Relevance

For an investor assessing sector exposure, the current healthcare repricing raises a specific question: has anything changed at the business level, or has the price simply followed the flow of capital out of a previously crowded trade. That distinction determines whether a reduced healthcare weighting reflects a genuine risk-adjusted return or a missed valuation opportunity, and it sits at the centre of how a high conviction fund approaches sector positioning after a broad repricing event.

Conclusion

The scale and uniformity of the decline across CSL, Cochlear, ResMed and Pro Medicus points to sector-wide degrossing, a mechanical reset that has moved faster than any change in fundamentals. That gap between price and business quality is where the current opportunity in ASX healthcare stocks concentrates.

To learn more about Datt Capital's approach to distinguishing valuation resets from genuine risk, visit our Investment Philosophy page or contact our Distribution Manager, Daniel Liptak, at 0419 004 524 or by email at daniel@datt.com.au.